Tag: DCLT

Big-Time Options Winners

Options Reviews

We got off to a very good start yesterday morning with our fresh options ideas. We’ll circle back to the longer term ideas later, but all of our weekly contracts produced nice gains as the markets saw a a healthy bull session following a brief early morning dip.

Here are the total possible profits on the day that were afforded by our targets. In the case of CGC and TLRY, premarket conditions today lead us to believe that we will see these gains extended even further: 

CGC Weekly $16-16.50 Calls
$16: .25-.72 (+188%)
$16.50: .18-.55 (+205%)
_____

TLRY Weekly $7-7.50 Calls
$7: .55-.99 (+80%)
$7.50: .36-.64 (+78%)
_____

TSN Weekly $57-55 Puts
$57: .94-3.25 (+246%)
$56.50: .88-2.70 (+207%)
$56: .77-2.55 (+231%)
$55: .55-1.95 (+255%)
_____

SPDR S&P500 (ETF) SPY – Recap 

On Friday morning, we had also updated our options targets for the SPY, signaling the 05/04 $282-283 Calls, and those put up some really nice numbers into yesterday’s expiration that we wanted to relay this morning.

05/04 $282-283 Calls
$282: .25-1.95 (+680%)
$283: .09-1.09 (+1111%)

Fresh Options Ideas:
CHGG 05/15 $45-55 Calls
GNMK 05/15 $10-15 Calls
PTON Weekly $34-35 Calls
SPY 05/06 $285-288 Calls

Extended Watchlist:
GOVX, GNPX, BTSC, GAHC, GMEV, DCLT, MVIS, TGTX, AKBA, KOPN, PCTY

Blue Horseshoe Stocks: SDOC Recap & More


SandRidge Energy, Inc. SDOC

Our mention of SDOC in Friday’s premarket report turned out to very well-timed. We’ve had the stock on our radars since early this year, and  pushed it to the back burner for awhile, having so many other items of interest on the table.

We circled back around to it on Friday, just in time to catch a solid single session performance as the stock ran from a low of a nickel up to .0674; that works out to a 35% intraday increase on fairly heavy volume.

We’ll continue to keep an eye on SDOC, which appears to be ready to gap-up slightly today, for a breach of the 50DMA at .08.

Celldex Therapeutics, Inc. CLDX

We’re going to tag CLDX this morning as a bottom-watch play with serious rebound potential. Our bottom-feeder alerts are sounding loudly as we’re seeing the stock take an absolute nosedive on news of the cancellation of the company’s late-stage brain tumor vaccine study.

We’re always on the lookout for knee-jerk selloffs (which often transition into recovery plays), and CLDX has lost roughly half its value solely on the perceived effect of the announcement.

It’s worth it to mention that the company still has seven clinical trials underway on other products, so the discontinued project is by no means the only thing in the company’s pipeline.

We’ll be interested to track the action in CLDX in coming sessions as investors adjust to this morning’s events.

Extended Watchlist:
DCLT, PVAH, GDPM, WRES, LNCO, BBEP, CLF, KEG